[{"id":"0fedf5e9-36db-42c2-931a-e84983c3f809","acronym":"PIER","url":"https://clinicaltrials.gov/study/NCT03000374","created_at":"2021-01-18T14:45:36.710Z","updated_at":"2024-07-02T16:36:15.193Z","phase":"Phase 2","brief_title":"Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery","source_id_and_acronym":"NCT03000374 - PIER","lead_sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 12/15/2021","study_completion_date":" 12/15/2021","last_update_posted":"2022-03-17"},{"id":"66ba0093-37f8-4c2f-8963-e9c495692bd9","acronym":"CircuLOR-1","url":"https://clinicaltrials.gov/study/NCT02827565","created_at":"2021-01-18T13:51:48.594Z","updated_at":"2024-07-02T16:37:08.102Z","phase":"","brief_title":"Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02827565 - CircuLOR-1","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS exon 2 mutation • BRAF exon 15 mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS exon 2 mutation • BRAF exon 15 mutation"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/03/2016","start_date":" 02/03/2016","primary_txt":" Primary completion: 01/05/2017","primary_completion_date":" 01/05/2017","study_txt":" Completion: 01/19/2017","study_completion_date":" 01/19/2017","last_update_posted":"2018-08-08"},{"id":"20b63c84-5fbb-4f76-a357-de7569544623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922583","created_at":"2021-01-18T08:40:42.278Z","updated_at":"2024-07-02T16:37:08.883Z","phase":"Phase 2","brief_title":"AUY922 in Patient With Stage IV NSCLC","source_id_and_acronym":"NCT01922583","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation","tags":["EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2018-07-18"}]